Table 2.

3-year, 5-year and 8-year Cumulative Incidence (%) of AML/MDS by Chemotherapy Regimens^*

AML
	N patients	3-year Cumulative Incidence		5-year Cumulative Incidence		8-year Cumulative Incidence
		N at Risk	% (95% CI)	N at Risk	% (95% CI)	N at Risk	% (95% CI)
All Subjects	92,110
Chemo Regimen
No Chemo	71,886	61,446	0.21 (0.18 – 0.25)	50,985	0.32 (0.13– 0.37)	27,697	0.45 (0.40 – 0.51)
A-based	3,797	3,395	0.41 (0.25 – 0.68)	3,058	0.53 (0.34 – 0.83)	2,218	0.90 (0.62 – 1.30)
A+T	8,338	7,316	0.40 (0.28 – 0.56)	6,165	0.61 (0.46 – 0.82)	3,546	0.84 (0.64 – 1.08)
TC	3,083	2,794	0.13 (0.05 – 0.36)	2,186	0.17 (0.07 – 0.41)	566	0.22 (0.10 – 0.51)
Other Taxane	2,851	2,215	0.23 (0.10 – 0.51)	1,690	0.33 (0.16 – 0.66)	560	0.33 (0.17 – 0.66)
CMF	2,155	1,899	0.15 (0.05 – 0.45)	1,614	0.37 (0.18 – 0.79)	1,064	0.72 (0.41 – 1.28)
MDS
	N patients	3-year Cumulative Incidence		5-year Cumulative Incidence		8-year Cumulative Incidence
		N at Risk	% (95% CI)	N at Risk	% (95% CI)	N at Risk	% (95% CI)
All Subjects	92,110
Chemo Regimen
No Chemo	71,886	61,191	0.62 (0.56 – 0.68)	50,704	0.88 (0.81 – 0.96)	27,535	1.11 (1.03 – 1.20)
A-based	3,797	3,362	1.26 (0.94 – 1.67)	3,021	1.72 (1.34 – 2.21)	2,190	2.24 (1.78 – 2.80)
A+T	8,338	7,274	0.90 (0.71 – 1.13)	6,120	1.23 (1.00 – 1.50)	3,519	1.55 (1.28 – 1.87)
TC	3,083	2,786	0.47 (0.28 – 0.79)	2,175	0.67 (0.42 – 1.04)	562	0.91 (0.59 – 1.38)
Other Taxane	2,851	2,195	1.07 (0.74 – 1.55)	1,671	1.38 (0.99 – 1.94)	553	1.66 (1.20 – 2.30)
CMF	2,155	1,882	0.97 (0.62 – 1.49)	1,593	1.37 (0.94 – 1.99)	1,050	2.19 (1.78 – 2.80)

^*Estimated from Kaplan-Meier Method; CI - Confidence Interval